Opportunistic infections after blood and marrow transplantation

Transplant Infectious Disease

Volumn 1, Issue 1, 1999, Pages 3-20

  Wingard, J R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Bone marrow transplant; Cytomegalovirus; Fungal infection; Opportunistic infection

Indexed keywords

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CLASSIFICATION; CYTOMEGALIC INCLUSION BODY DISEASE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOLOGY; MYCOSIS; OPPORTUNISTIC INFECTION; POSTOPERATIVE COMPLICATION; REVIEW;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HUMANS; MYCOSES; OPPORTUNISTIC INFECTIONS; POSTOPERATIVE COMPLICATIONS;

EID: 0033086265     PISSN: 13982273     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-3062.1999.10102.x     Document Type: Article

References (172)

1. BODEY GP, BUCKLEY M, SATHE YS, et al. Quantitative relationship between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966: 64: 328-340.
2. GURNEY H. The problem of neutropenia resulting from cancer therapy. Clinician 1989: 7: 2-10.
3. WINSTON DJ, GALE RP, MEYER DV, et al. Infectious complications of human bone marrow transplantation. Medicine 1979: 58: 1-31.
4. GERSON SL, TALBOT GH, HURWITZ S, et al. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in acute leukemia. Arch Intern Med 1984: 100: 345-351.
5. BOW EJ, LOEWEN R, CHEANG MS, SCHACTER B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: The pathogenetic role of the antileukemia regimen. Clin Infect Dis 1995: 21: 361-369.
6. BOW EJ, CHEONG MS, SHORE TB, et al. Cytotoxic therapy-induced D-xylose malabsorption and invasive infection during remission-induction therapy for acute myeloid leukemia in adults. J Clin Oncol 1997: 15: 2254-2261.
7. WINGARD JR, DICK JD, MERZ WG, et al. Differences in virulence of clinical isolates of Candida tropicalis and Candida albicans in mice. Infect Immun 1982: 37: 833-836.
8. WINGARD JR. Infectious and noninfectious systemic consequences. Oral complications of cancer therapies: Diagnosis, prevention, and treatment. NCI Monogr 1990: 9: 21-26.
9. VILLABLANCA JG, STEINER M, KERSEY J, et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 1990: 6: 387-393.
10. STEINER M, VILLABLANCA JG, KERSEY J, et al. Viridans streptococcal shock in bone marrow transplantation patients. Am J Hematol 1993: 42: 354-358.
11. VALTEAU D, HARTMANN O, BRUGIERES L, et al. Streptococcal septicemia following autologous bone marrow transplantation in children treated with high-dose chemotherapy. Bone Marrow Transplant 1991: 7: 415-419.
12. CLASSEN DC, BURKE JP, FORD CD, et al. Streptococcus mitis sepsis in bone marrow transplant patients receiving oral antimicrobial prophylaxis. Am J Med 1990: 89: 441-446.
13. BOCHUD P, CLANDRA T, FRANCIOLI P. Bacteremia due to viridans streptococci in neutropenic patients: A review. Am J Med 1994: 97: 256-264.
14. WINGARD JR, MERZ WG, RINALDI MG, et al. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with Fluconazole. N Engl J Med 1991: 325: 1274-1277.
15. WINGARD JR, MERZ W, RINALDI M, et al. Association of Torulopsis Glabrata infections with Fluconazole prophylaxis in neutropenic bone marrow transplant patients. Antimicrob Agents Chemothr 1993: 37: 1847-1849.
16. WINGARD JR. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clinical Infectious Diseases 1995: 20: 115-125.
17. VAZQUEZ JA, SANCHEZ V, DMUCHOWSKI C, et al. Nosocomial acquisition of Candida albicans: An epidemiologic study. J Infect Dis 1993: 168: 195-201.
18. MORRISON VA, HAAKE RJ, WEISDORF DJ. The spectrum of non-Candida fungal infections following bone marrow transplantation. Medicine 1993: 72: 78-89.
19. ROSE HD. Mechanical control of hospital ventilation and Aspergillus infections. Am Rev Respir Dis 1972: 105: 306-307.
20. ROTSTEIN C, CUMMINGS KM, TIDINGS J, et al. An outbreak of invasive aspergillosis among allogeneic bone marrow transplants: A case-control study. Infect Control 1985: 6: 347-355.
21. MAHONEY DH JR, STEUBER CP, STARLING KA, et al. An outbreak of aspergillosis in children with acute leukemia. J Pediatr 1979: 95: 70-72.
22. LENTINO JR, ROSENKRANZ MA, MICHAELS JA, et al. Nosocomial aspergillosis: A retrospective review of airborne disease secondary to road construction and contaminated air conditioners. Am J Epidemiol 1982: 116: 430-437.
23. AISNER J, SCHIMPFF SC, BENNETT JE, et al. Aspergillus infections in cancer patients: Association with fireproofing materials in a new hospital. JAMA 1976: 235: 411-412.
24. MEYERS JD, FLOURNOY N, THOMAS ED. Infection with herpes simplex virus and cell-mediated immunity after marrow transplant. J Infect Dis 1980: 142: 142-146.
25. SARAL R, BURNS WH, LASKIN OL, et al. Acyclovir prophylaxis of herpes simplex virus infections. A randomized, double-blind, controlled trial in bone marrow transplant recipients. N Eng J Med 1981: 305: 63-67.
26. SAYER HG, LONGTON G, BOWDEN R, et al. Increased risk of infection in marrow transplant patients receiving methylprednisolone for graft-versus-host disease prevention. Blood 1994: 84: 1328-1332.
27. O'DONNELL MR, SCHMIDT GM, TEGTMEIER BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: Impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994: 12: 827-834.
28. MYERS J. Fungal infections in bone marrow transplant patients. Semin Oncol 1990: 17: 10-13.
29. JANTUNEN E, RUUTU P, NISKANEN L, et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplant 1997: 19: 801-808.
30. WALD A, LEISENRING W, VAN BURIK JA, BOWDEN RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997: 175: 1459-1466.
31. MEYERS JD, FLOURNOY N, THOMAS ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis 1986: 153: 478-488.
32. MILLER W, FLYNN P, MCCULLOUGH J, et al. Cytomegalovirus infection after marrow transplantation: An association with acute graft-versus-host disease. Blood 1986: 67: 1161-1167.
33. WINGARD JR, CHEN DY-H, BURNS WH, et al. Cytomegalovirus infection after autologous bone marrow transplantation: Comparison to infection after allogeneic bone marrow transplantation. Blood 1988: 71: 1432-1437.
34. REUSSER P, FISHER LD, BUCKNER CD, et al. Cytomegalovirus infection after autologous bone marrow transplantation: Occurrence of cytomegalovirus disease and effect on engraftment. Blood 1990: 75: 1888-1894.
35. WINGARD JR, PIANTADOSI S, BURNS WH, et al. Cytomegalovirus infections in patients treated by intensive cytoreductive therapy with marrow transplant. Rev Infect Dis 1990: 12 (Suppl 7): S793-S804.
36. WINSTON DJ, HO WG, CHAMPLIN RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990: 12 (Suppl 7): S776-792.
37. ZAIA JA. Viral infections associated with bone marrow transplantation. Hematol/Oncol Clin North Am 1990: 4: 603-623.
38. LJUNGMAN P, BIRON P, BOSI A, et al. Cytomegalovirus intersititial pneumonia in autologous bone marrow transplant patients. Bone Marrow Transplant 1994: 13: 209-212.
39. MEYERS JD, SPENCER HC JR, WATTS JC, et al. Cytomegalovirus pneumonia after human marrow transplantation. J Infect Dis 1986: 13: 478-488.
40. BOWDEN RA, SLICHTER SJ, SAYERS MH, et al. Use of leukocyte-depleted platelets and cytomegalovirus-seronegative red blood cells for prevention of primary cytomegalovirus infection after marrow transplant. Blood 1991: 78: 246-250.
41. DEWITTE T, SCHATTENBEREG A, VAN DIJK BA, et al. Prevention of primary cytomegalovirus infection by using leukocyte-poor random blood products from cytomegalovirus-unscreened blood-bank donors. Transplantation 1990: 50: 964-968.
42. WINSTON DJ, HO WG, HOWELL CL, et al. Cytomegalovirus infections associated with leukocyte transfusions. Ann Intern Med 1980: 93: 671-675.
43. MEYERS JD, LJUNGMAN P, FISHER LD. Cytomegalovirus excretion as a predictor of cytomeglovirus disease after marrow transplantation: Importance of cytomegalovirus viremia. J Infect Dis 1990: 162: 373-380.
44. BOECKH M, BOWDEN RA, GOODRICH JM, et al. Cytomegalovirus antigen detection in peripheral blood leukocytes after allogeneic marrow transplantation. Blood 1992: 80: 1358-1364.
45. VAN DER BIJ W, TORENSMA R, VAN SON WJ, et al. Rapid immunodiagnosis of active cytomegalovirus infection by monoclonal antibody staining of blood leucocytes. J Med Virol 1988: 25: 179-188.
46. JIWA NM, VAN DE RIJKE FM, MULDER A, et al. An improved immunocytochemical method for detection of human cytomegalovirus antigens in peripheral blood leucocytes. Histochemistry 1989: 91: 345-349.
47. SPECTOR SA, MERRILL R, WOLF D, et al. Detection of human cytomegalovirus in plasma of AIDS patients during acute viseral disease by DNA amplification. J Clin Microbiol 1992: 30: 2359-2365.
48. BRYTTING M, XU W, WAHREN B, et al. Cytomegalovirus DNA detection in sera from patients with active cytomegalovirus infections. J Clin Microbiol 1992: 30: 1937-1941.
49. EINSELE H, STEIDLE M, VALLBRACHT A, et al. Early occurrence of human cytomegalovirus infection after bone marrow transplantation as deomonstrated by the polymerase chain reaction technique. Blood 1991: 77: 1104-1110.
50. NOLTE FS, EMMENS RK, THURMOND C, et al. Early detection of human cytomegalovirus viremia in bone marrow transplant recipients by DNA amplification. J Clin Microbiol 1995: 33: 1263-1266.
51. ATKINSON K, ARTHUR C, BRADSTOCK K, et al. Prophylactic ganciclovir is more effective in HLA-identical family member marrow transplant recipients than in more heavily immunesuppressed HLA-identical unrelated donor marrow transplant recipients. Bone Marrow Transplant 1995: 16: 401-405.
52. ENRIGHT H, HAAKE R, WEISDORF D, et al. Cytomegalovirus pneumonia after bone marrow transplantation. Transplantation 1993: 55: 1339-1346.
53. HERTENSTEIN B, HAMPL W, BUNJES D, et al. In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 1995: 15: 387-393.
54. TAKENAKA K, GONDO H, TANIMOTO K, et al. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. Bone Marrow Transplant 1997: 19: 241-248.
55. DE LA CAMARA R, FERNANDEZ-RANADA JM. Increased incidence of CMV infection after allogeneic bone marrow transplantation from unrelated donors but doubts about an increase in CMV-associated disease. Bone Marrow Transplant 1997: 20: 181.
56. ATKINSON K, STORB R, PRENTICE RL, et al. Analysis of late infections in 89 long-term survivors of bone marrow transplantation. Blood 1979: 53: 720-731.
57. ATKINSON K, FAREWELL V, STORB R, et al. Analysis of late infections after human bone marrow transplantation: Role of genotypic nonidentity between marrow donor and recipient and of nonspecific suppressor cells in patients with chronic graft-versus-host disease. Blood 1982: 60: 714-720.
58. KERNAN NA, BARTSCH G, ASH RC, et al. Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program. N Eng J Med 1993: 328: 593-602.
59. OCHS L, SHU XO, MILLER J, et al. Late infectins after allogeneic bone marrow transplantation: Comparison of incidence in related and unrelated donor transplant recipients. Blood 1995: 86: 3979-3986.
60. SULLIVAN KM, AGURA E, ANASETTI C, et al. Chronic graft-versus-host disease and other late complications of bone marrow transplantation. Semin Hematol 1991: 28: 250-259.
61. SULLIVAN KM, NIMS J, LEISENRING W, et al. Determinants of late infection following marrow transplantation for aplastic anemia and myelodysplastic syndrome. Blood 1995: 86 (Suppl 1): 213a.
62. SULLIVAN KM, MORI M, SANDERS J, et al. Late complications of allogeneic and autologous marrow transplantation. Bone Marrow Transplant 1992: 10: 127-134.
63. HOYLE C, GOLDMAN JM. Life-threatening infections occurring more than 3 months after BMT. Bone Marrow Transplant 1994: 14: 247-252.
64. WINSTON DJ, SHIFFMAN G, WANG D, et al. Pneumococcal infections after human bone marrow transplantation. Ann Intern Med 1979: 91: 835-841.
65. SULLIVAN KM, SHULMAN HM, STORB R, et al. Chronic graft-versus-host disease in 52 patients. Adverse natural course and successful treatment with combination immunosuppression. Blood 1981: 57: 267-276.
66. ZAIA JA, GALLEZ-HAWKINS GM, TEFTMEIER BR, et al. Late cytomegalovirus disease in marrow transplantation is predicted by virus load in plasma. J Infect Dis 1997: 176: 782-785.
67. EINSELE H, HEBART H, KAUFFMANN C, et al. Late onset CMV disease after allogeneic stem cell transplantation. Bone Marrow Transplant 1997: 19 (Suppl 1): S85.
68. LI CR, GREENBERG PD, GILBERT MJ, et al. Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: Correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 1994: 83: 1971-1979.
69. GOR D, SABIN C, PRENTICE HG, et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: Relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998: 21: 597-405.
70. KRAUSE H, HEBART H, JAHN G, et al. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant 1997: 19: 1111-1116.
71. SHEARER WT, RITZ J, FINEGOLD MJ. Epstein-Barr virus-associated B-cell proliferations of diverse clonal origins after bone marrow transplantation in a 12 year old patient with severe combined immunodeficiency. N Eng J Med 1985: 312: 1151-1159.
72. MARTIN PJ, SHULMAN HM, SCHUBACH WH. Fatal Epstein-Barr-virus-associated proliferation of donor B cells after treatment of acute-graft-versus-host disease with a murine anti-T-cell antibody. Ann Intern Med. 1984: 101: 310-315.
73. ZUTTER MM, MARTIN PJ, SALE GE, et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988: 72: 520-529.
74. D'AMORE ESG, MANIVEL JC, GAJL-PECZALSKA KJ, et al. B-cell lymphoproliferative disorders after bone marrow transplant: An analysis of ten cases with emphasis on Epstein-Barr virus detection in-situ hybridization. Cancer 1991: 68: 1285-1295.
75. COLBY BM, SHAW JE, ELION GB, PAGANO JS. Effect of acyclovir (9-2-hydroxyethoxymethyl) guanine on Epstein-Barr virus DNA replication. J Virol 1980: 34: 560-568.
76. ANDERSON J, BRITTON S, ERNBERG I, et al. Effect of acyclovir on infectious mononucleosis: A double-blind, placebo-controlled study. J Infect Dis 1986: 153: 282-286.
77. LUCAS KG, BURTON RL, ZIMMERMAN SE, et al. Semiquantitative Epstein-Barr Virus (EBV) polymerase chain reaction for the determination of patients at risk for EBV-induced lymphoproliferative disease after stem cell transplantation. Blood 1998: 91: 3654-3661.
78. HALE G, WALDMANN H. Risks of developing Epstein-Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. Bood 1998: 91: 3079-3083.
79. ATKINSON K, MEYERS JD, STORB R, et al. Varicella-zoster virus infection after marrow transplantation for aplastic anemia or leukemia. Transplantation 1980: 29: 47-50.
80. LOCKSLEY PRM, FLOURNOY N, SULLIVAN KM, MEYERS JD. Infection with varicella-zoster virus after marrow transplantation. J Infect Dis 1985: 152: 1172.
81. SCHUCHTER LM, WINGARD JR, PIANTADOSI S, et al. Herpes zoster infection after autologous bone marrow transplantation. Blood 1989: 74: 1424-1427.
82. HAN CS, MILLER W, HAAKE R, WEISDORF D. Varicella zoster infection after bone marrow transplantation: Incidence, risk factors and complications. Bone Marrow Transplant 1994: 13: 277-283.
83. SICKLES EA, GREEN WH, WIERNICK PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975: 135: 715-719.
84. WINGARD JR, SANTOS GW, SARAL R. Differences between first and subsequent fevers during prolonged neutropenia. Cancer 1987: 59: 844-849.
85. KUHLMAN JE, FISHMAN EK, BURCH PA, et al. Invasive pulmonary aspergillosis in acute leukemia: The contribution of CT to early diagnosis and aggressive management. Chest 1987: 82: 95-99.
86. PASTALOZZI BC, KRESTIN GP, SCHANZ U, et al. Hepatic lesions of chronic disseminated candidiasis may become invisible during neutropenia. Blood 1997: 90: 3858-3864.
87. THALER M, PASTAKIA B, SHAWKER TH, et al. Hepatic candidiasis in cancer patients: The evolving picture of the syndrome. Ann Intern Med 1988: 108: 88-100.
88. APPELBAUM FR, MEYERS JD, FEFER A, et al. Nonbacterial nonfungal pneumonia following marrow transplantation in 100 identical twins. Transplantation 1982: 46: 61-65.
89. WINGARD JR, SOSTRIN MB, VRIESENDORP HM, et al. Interstitial pneumonitis following autologous bone marrow transplantation. Transplantation 1988: 46: 61-65.
90. WEINER RS, BORTIN MM, GALE RP, et al. Interstitial pneumonitis after bone marrow transplantation. Ann Intern Med 1986: 104: 168-175.
91. WINGARD JR, MELLITS ED, SOSTRIN MB, et al. Intersititial pneumonitis after allogeneic bone marrow transplantation: Nine-year experience at a single institution. Medicine (Baltimore) 1988: 67: 175-186.
92. WHIMBY E, BODEY GP. Viral pneumonia in the immunocompromised adult with neoplastic disease: The role of common community respiratory viruses. Semin Respir Infect 1992: 7: 122-126.
93. HERTZ MI, ENGLUND JA, SNOVER D, et al. Respiratory syncytial virus-induced acute lung injury in adult patients with bone marrow transplants: A clinical approach and review of the literature. Medicine 1989: 68: 269.
94. WHIMBEY E, ELTING LS, COUGH RB, et al. Influenza A virus infections among hospitalized adult bone marrow transplant recipients. Bone Marrow Transplant 1994: 13: 437-441.
95. WHIMBY E, VARTIVARIAN SE, CHAMPLIN SE, et al. Parainfluenza virus infection in adult bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1993: 12: 690-695.
96. WENDT CH, WEISDORF DJ, JORDAN MC, et al. Parainfluenza virus respiratory infection after bone marrow transplantation. N Eng J Med 1992: 325: 921-926.
97. SHIELDS AF, HACKMAN RC, FIFE KH, et al. Adenovirus infection in patients undergoing bone marrow transplantation. N Eng J Med 1985: 312: 529-533.
98. FLOMEMBERG P, BABBITT J, DROBYSKI WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis 1994: 169: 775-781.
99. CARRIGAN DR, DROBYSKI WR, RUSSLER SK, et al. Interstitial pneumonitis associated with human herpesvirus six (HHV-6) infection in marrow transplant patients. Lancet 1991: 338: 147-149.
100. SCHWEBKE JR, HACKMAN R, BOWDEN R. Pneumonia due to Legionella micdadei in bone marrow transplant recipients. Rev Infect Dis 1990: 12: 824-828.
101. CONE RW, HACKMAN RC, HUANG MW, et al. Human herpesvirus 6 in lung tissue from patients with pneumonitis after bone marrow transplantation. N Eng J Med 1993: 329: 156-161.
102. ROBBINS RA, LINDER J, STAHL MG, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med 1989: 87: 511-518.
103. DELORENZO LJ, HUANG CT, MAQUIRE GP, et al. Roentgenographic patterns of Pneumocystis carinii pneumonia in 104 patients with AIDS. Chest 1987: 91: 323-327.
104. ARTHUR RR, SHAH KV, BAUST SJ, et al. Association of BK viruria with hemorrhagic cystitis in recipients of bone marrow transplantation. N Eng J Med 1986: 315: 230-234.
105. RUSSELL SJ, VOWELS MR, VALE T. Haemorrhagic cystitis in paediatric bone marrow transplant patients: An association with infective agents, GVHD and prior cyclophosphamide. Bone Marrow Transplant 1994: 13: 533-539.
106. AZZI A, FANCI R, BOSI A, et al. Monitoring of polyomavirus BK viruria in bone marrow transplantation patients by DNA hybridization assay and by polymerase chain reaction: An approach to assess the relationship between BK viruria and hemorrhagic cystitis. Bone Marrow Transplant 1994: 14: 235-240.
107. SCHNEIDER EM, DORRIES K. High frequency of polyomavirus infection in lymphoid cell preparations after allogeneic bone marrow transplantation. Transplant Proc 1993: 25: 1271-1273.
108. AMBINDER RF, BURNS W, FORMAN M, et al. Hemorrhagic cystitis associated with adenovirus infection in bone marrow transplantation. Arch Intern Med 1986: 146: 1400-1401.
109. YOLKEN RH, BISHOP CA, TOWNSEND TR, et al. Infectious gastroenteritis in bone marrow transplant recipients. N Eng J Med 1982: 306: 1010-1012.
110. HACKMAN RC, WOLFORD JL, GLEAVES CA, et al. Recognition and rapid diagnosis of upper gastrointestinal cytomegalovirus infection in marrow transplant recipients. Transplantation 1994: 57: 231-237.
111. TROUSSARD X, BAUDUER F, GALLET E, et al. Virus recovery from stools of patients undegoing bone marrow transplantation. Bone Marrow Transplant 1993: 12: 573-578.
112. TOWNSEND TR, BOLYARD EA, YOLKEN RH, et al. Outbreak of coxsackie A1 gastroenteritis: A complication of bone marrow transplantation. Lancet 1982: 1: 820-923.
113. DROBYSKI WR, DUNNE WM, BURD EM. Human herpesvirus 6 (HHV6) infection in allogeneic bone marrow transplant recipients: I. Evidence for a marrow suppressive role for HHV-6 in vivo. J Infect Dis 1993: 167: 735-823.
114. KNOX KK, CARRIGAN DR. In vitro suppression of bone marrow progenitor cell differentiation by human herpesvirus 6 infection. J Infect Dis 1992: 165: 925-929.
115. CARRIGAN DR, KNOX KK. Human herpesvirus 6 (HHV6) isolation from bone marrow: HHV-6-associated bone marrow suppression in bone marrow transplant patients. Blood 1994: 84: 3307-3310.
116. GUSSACK GS, BURSON JG, HUDGINS P, et al. Sinusitis in the bone marrow transplant patient: Diagnosis and management. Am J Rhinol 1995: 9: 1-5.
117. DEUTSCH JG, HUDGINS PA, SIEGEL JL, et al. The paranasal sinuses in patients with acute graft-versus-host disease. Am J Neuroradiol 1995: 16: 1287-1291.
118. SCHILLER GJ, NIMER SD, GAJEWSKI JL, GOLDE D. Abdominal presentation of varicella-zoster infection in recipients of allogeneic bone marrow transplantation. Bone Marrow Transplant 1991: 7: 489-491.
119. HUGHES WT, ARMSTRONG D, BODEY GP, et al. 1997 Guidelines for the use of antimicrobial agents in enutropenic patients with unexplained fever. Clin Infect Dis 1997: 25: 551-573.
120. CENTERS FOR DISEASE CONTROL AND PREVENTION. Recommendations for preventing the spread of vancomycin resistance recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). Morbid Mortal Weekly Rep 1995: 44: 1013-1020.
121. GOLDMAN DA, WEINSTEIN RP, WENZEL RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: A challenge to hospital leadership. JAMA 1996: 275: 234-240.
122. SHLAES DM, GERDING DN, JOHN JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the prevention of antimicrobial resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997: 25: 584-599.
123. DE PAUW BE, MEIS JFGM. Progress in fighting systemic fungal infections in haematological neoplasia. Support Care Cancer 1998: 6: 31-38.
124. LAM HH, ALTHAUS BL. Antifungal prophylaxis in bone marrow transplant. Ann Pharmacother 1995: 29: 921-924.
125. WALSH TJ, HIEMENZ JW, ANAISSIE E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996: 10: 365-400.
126. UZUN O, ANAISSIE EJ. Problems and controversies in the management of hematogenous candidiasis. Clin Infect Dis 1996: 22 (Suppl 1): S73-S88.
127. FORMAN SJ, ZAIA JA. Treatment and prevention of cytomegalovirus pneumonia after bone marrow transplantation: Where do we stand? Blood 1994: 83: 2392-3398.
128. GOODRICH JM, BOECKH M, BOWDEN R. Strategies for the prevention of cytomegalovirus disease after marrow transplantation. Clin Infect Dis 1994: 19: 287-298.
129. WINGARD JR. Viral infections in leukemia and bone marrow transplant patients. Leuk Lymphoma 1993: 11: 115-125.
130. TSINONTIDES AC, BECHTEL TP. Cytomegalovirus prophylaxis and treatment following bone marrow transplantation. Ann Pharmacother 1996: 30: 1277-1290.
131. PRENTICE HG, KHO P. Clinical strategies for the management of cytomegalovirus infection and disease in allogeneic bone marrow transplant. Bone Marrow Transplant 1997: 19: 135-142.
132. BADAS A, STOUKIDES CA. Guidelines for prophylaxis of cytomegalovirus disease in bone marrow transplant patients. Ann Pharmacother 1996: 30: 1483-1486.
133. SERODY JS, SHEA TC. Prevention of infections in bone marrow transplant recipients. Infect Dis Clin North Am 1997: 11: 459-477.
134. LEW MA, KEHOE K, RITZ J, et al. Ciprofloxacin versus trimethoprim/sulfamethoxazole for prophylaxis of bacterial infections in bone marrow transplant recipients: A randomized, controlled trial. J Clin Oncol 1995: 13: 239-250.
135. JANSEN J, CROMER M, AKARD L, et al. Infection prevention in severely myelosuppressed patients: A comparison between ciprofloxacin and a regimen of selective antibiotic modulation of the intestinal flora. Am J Med 1994: 96: 335-341.
136. KERN W, KURRLE E, SCHMEISER T. Streptococcal bacteremia in adult patients with leukemia undergoing aggressive chemotherapy: A review of 55 cases. Infection 1990: 18: 138-145.
137. DEPAUW BE, DONNELLY JP, DE WITTE T, et al. Options and limitations of long-term ciprofloxacin as antibacterial prophylaxis in allogeneic bone marrow transplant recipients. Bone Marrow Transplant 1991: 5: 179-182.
138. BOW EJ, RAYNER E, LOUIE TJ. Comparison of norfloxacin with cotrimoxazole for infectious prophylaxis in acute leukemia. Am J Med 1988: 84: 847-854.
139. SARAL R. Management of acute viral infections. NCI Monogr 1990: 9: 107-110.
140. WADE JC, MCLAREN C, MEYERS JD. Frequency and significance of acyclovir-resistant herpes simplex virus isolated from marrow transplant patients receiving multiple courses of treatment with acyclovir. J Infect Dis 1983: 148: 1077-1081.
141. BRATANOW NC, ASH RC, TURNER PA. Successful treatment of serious cytomegalovirus (CMV) disease with 9(1,3-dihydroxy-2-propoxymethyl) guanine (ganciclovir), DHPG) and intravenous immunoglobulin (IVIG) in bone marrow transplant (BMT) patients. Exp Hematol 1987: 15: 541.
142. EMANUEL D, CUNNINGHAM I, JULES-ELYSEE K, et al. Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combnation of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 1988: 109: 777-782.
143. REED EC, BOWDEN R, DANDLIKER PS, et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 1988: 109: 783-788.
144. SCHMIDT GM, KOVACS A, ZAIA JA, et al. Ganciclovir/immunoglobulin combination therapy for the treatment of human cytomegalovirus-associated interstitial pneumonia in bone marrow allograft recipients. Transplantation 1988: 46: 905-907.
145. WINSTON DJ, HO WG, CHAMPLIN RE. Cytomegalovirus infections after allogeneic bone marrow transplantation. Rev Infect Dis 1990: 12: S776-S792.
146. BOWDEN RA, SAYERS M, FLOURNOY N, et al. Cytomegalovirus immune globulin and seronegative blood products to prevent primary cytomeglovirus infection after marrow transplantation. N Eng J Med 1986: 314: 1006-1010.
147. MACKINNON S, BURNETT AK, CRAWFORD RJ, et al. Seronegative blood products prevent primary cytomegalovirus infection after bone marrow transplantation. J Clin Pathol 1988: 41: 948-950.
148. MILLER W, MCCULLOUGH J, BALFOUR HH, et al. Prevention of CMV infection by blood products: A randomized trial. J Cell Biochem 1988: 12 (Suppl C): 93.
149. WINSTON DJ, HO WG, LIN CH, et al. Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern med 1987: 106: 12-18.
150. BASS EB, POWE NR, GOODMAN SN, et al. Efficacy of intravenous immune globulin in preventing complications of bone marrow transplantation: A meta analysis. Bone Marrow Transplant 1993: 12: 273-282.
151. MESSORI A, RAMPAZZO R, SCROCCARO G, MARTINI N. Efficacy of hyperimmune anti-cytomegalovirus immunoglobulins for the prevention of cytomegalovirus infection in recipients of allogeneic bone marrow transplantation: a meta-analysis. Bone Marrow Transplant 1994: 13: 163-167.
152. BOWDEN RA, FISHER LD, ROGERS K, et al. Cytomegalovirus (CMV)-specific intravenous immunoglobulin for the prevention of primary CMV infection and disease after marrow transplant. J Infect Dis 1991: 164: 483-487.
153. GUGLIELMO BJ, WONG-BERINGER A, LINKER CA. Immune globulin therapy in allogeneic bone marrow transplantation: A critical review. Bone Marrow Transplant. 1994: 13: 499-510.
154. SULLIVAN KM, KOPECKY KJ, JOCUM J, et al. Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Eng J Med 1990: 323: 705-712.
155. MEYERS JD, REED EC, SHEPP DH, et al. Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Eng J Med 1988: 318: 70-75.
156. PRENTICE HG, GLUCKMAN E, POWLES RL, et al. Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. Lancet 1994: 343: 749-753.
157. SCHMIDT GM, HORAK DA, NILAND JC, et al. A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplant patients. N Eng J Med 1991: 324: 1005-1011.
158. GOODRICH JM, MORI M, GLEAVES CA, et al. Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplant. N Eng J Med 1991: 325: 1601-1607.
159. GOODRICH JM, BOWDEN RA, FISHER L, et al. Ganciclovir prophylaxis to prevent cytomegalovirus disease after allogeneic marrow transplant. Ann Intern Med 1993: 118: 173-178.
160. WINSTON DJ, HO WG, BARTONI K, et al. Ganciclovir prophylaxis of cytomegalovirus infection and disease in allogeneic bone marrow transplant recipients. Ann Intern Med 1993: 118: 179-184.
161. VERDONCK LF, DEKKER AW, ROZENBERT-ARSKA M, VAN DEN HOEK M. A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 1997: 24: 901-907.
162. BOECKH M, GOOLEY TA, MYERSON D, et al. Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: A ramdomized double-blind study. Blood 1996: 10: 4063-4071.
163. SALZBERGER B, BOWDEN RA, HACKMAN RC, et al. Neutropenia in allogeneic marrow transplant recipients receiving ganciclovir for prevention of cytomegalovirus disease: Risk factors and outcome. Blood 1997: 90: 2502-3508.
164. QUINAN GV JR, KIRMANI N, ROOK AH, et al. Cytotoxic cells in cytomegalovirus infections. HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone marrow transplant recipients. N Eng J Med 1982: 307: 7-13.
165. REUSSER P, RIDDEL SR, MEYERS SD, GREENBERG PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: Pattern of recovery and correlation with cytomegalovirus infection and disease. Blood 1991: 78: 1373-1380.
166. QUINNAN GV JR, BURNS WH, KIRMANI N, et al. HLA-restricted cytotoxic T lymphocytes are an early immune response and important defense mechanism in cytomegalovirus infections. Rev Infect Dis 1984: 6: 156-163.
167. HANSEN JA, GOOLEY TA, MARTIN PJ, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Eng J Med 1998: 338: 962-968.
168. GOODMAN JL, WINSTON DJ, GREENFIELD RA. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Eng J Med 1992: 326: 845-851.
169. SLAVIN MA, OSBORNE B, ADAMS R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - A prospective, randomized, double-blind study. J Infect Dis 1995: 171: 1545-1552.
170. RICHARD C, ROMON I, BARO J, et al. Invasive pulmonary aspergillosis prior to BMT in acute leukemia patients does not predict a poor outcome. Bone Marrow Transplant 1993: 12: 237-241.
171. GARNER JS, HOSPITAL LNFECTION CONTROL PRACTICES ADVISORY COMMITTEE, CENTERS FOR DISEASE CONTROL AND PREVENTION. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol 1996: 17: 53-60.
172. CRAWFORD SW, BOWDEN RA, HACKMAN RC, et al. Rapid detection of cytomegalovirus pulmonary infection by bronchoalveolar lavage and centrifugation culture. Ann Intern Med 1988: 108: 180-185.